Kyzgaldak Ramazanova§
a,
Soumyadeep Chakrabortty§
b,
Bernd H. Müllerb,
Peter Lönnecke
a,
Johannes G. de Vries
*b and
Evamarie Hey-Hawkins
*a
aInstitute of Inorganic Chemistry, Universität Leipzig, Johannisallee 29, D-04103 Leipzig, Germany. E-mail: hey@uni-leipzig.de
bLeibniz Institute for Catalysis e.V., Albert-Einstein-Strasse 29a, 18059 Rostock, Germany. E-mail: Johannes.deVries@catalysis.de
First published on 24th November 2023
A convenient synthesis of enantiopure mixed donor phosphine–phosphite ligands has been developed incorporating P-stereogenic phosphanorbornane and axially chiral bisnaphthols into one ligand structure. The ligands were applied in Pd-catalyzed asymmetric allylic substitution of diphenylallyl acetate, Rh-catalyzed asymmetric hydroformylation of styrene and Rh-catalyzed asymmetric hydrogenation of an acetylated dehydroamino ester. Excellent branched selectivity was observed in the hydroformylation although low ee was found. Moderate ee's of up to 60% in allylic substitution and 50% in hydrogenation were obtained using bisnaphthol-derived ligands.
![]() | ||
Scheme 1 Synthetic protocol for 1-phosphanorbornane alcohol L1 (top) and pathway for the synthesis of phosphine–phosphite ligands 9a, b and L2, L3 (bottom). |
Herein, we report the synthesis of 1-phosphanorbornane-based P-stereogenic mixed donor bidentate ligands and their application in Pd-catalyzed asymmetric allylic substitution of benchmark diphenylallyl acetate, Rh-catalyzed asymmetric hydrogenation of methyl (Z)-2-acetamido-3-phenylacrylate and Rh-catalyzed asymmetric hydroformylation of styrene.
For the synthesis of bidentate (R)- or (S)-BINOL-based mixed donor ligands from 7, two possible pathways were studied (Scheme 1, bottom). Path I involves the reaction of enantiopure BINOL-based chlorophosphites, which were prepared employing a general procedure for chlorophosphites,34 with sulfur-protected PNA 7 in the presence of a mild base (such as NEt3), followed by deprotection to give L2, L3. The mild reducing agent Raney Ni was used as desulfurizing reagent in this case in view of its high selectivity and facile work-up, as lithium aluminum hydride (LAH) also attacks the phosphite P(OR)3 motif in 8a, b. Path II started with deprotection of 7 to afford L1 by either Raney Ni or LAH, followed by reaction with the corresponding chlorophosphites. However, the 31P{1H} NMR spectrum of the reaction mixture showed several signals for unidentified products, rendering this pathway unsuitable.
P-stereogenic 1-phosphanorbornane alcohol L1 and the phosphine–phosphites L2, L3 were fully characterized by NMR spectroscopy and high-resolution mass spectrometry. In the 31P{1H} NMR spectra (CDCl3), L1 exhibits a singlet at −45.9 ppm, while two singlets are observed for L2 (135.4 and −44.7 ppm) and L3 (139.4 and −44.7 ppm) which are characteristic signals for phosphites and phosphines, respectively.
Intermediates 8a, b were sulfurized to obtain the double sulfur-protected air- and moisture-stable compounds 9a, b (Scheme 1, bottom). The compounds were isolated by slowly cooling down a hot iPrOH solution and storing at −25 °C overnight. The structures of 9a, b were confirmed by NMR spectroscopy and HRMS. Single crystals of 9b (S-protected analogue of L3) suitable for X-ray crystal structure determination were obtained by slow evaporation of solvent from an ethyl acetate solution of 9b; any other method resulted in formation of powder only due to rapid nucleation. Excellent chemical (98–100%) and optical purities of 9a, b were verified by chiral HPLC (ESI, Fig. S23 and S24‡), thus also indirectly confirming the optical purities of L2 and L3.
As shown in Fig. 2, both phosphorus atoms in compound 9b have a distorted tetrahedral environment. The P–O bond lengths of the phosphite moiety are in the range of 156.6–159.8 pm in agreement with the literature.35 Moreover, both PS bond lengths (188.9 pm and 194.0 pm) are comparable to those reported previously.36
The Pd-catalyzed enantioselective allylation37 is an important method for C–C or C–heteroatom bond formation, where hybrid bidentate phosphines (P,P′), bulky monodentate phosphines (mostly phosphoramidites) and P,N ligands (P, oxazoline) have been employed successfully. The PNA (L1) and phosphine–phosphite ligands (L2, L3) were tested in the Pd-catalyzed asymmetric allylic alkylation of diphenylallyl acetate using dimethyl malonate as C-based nucleophile. Low conversion of diphenylallyl acetate was observed employing monodentate PNA (L1) (Pd/L1 = 1:
2) resulting in only 15% ee (entry 1, Table 1). Higher conversions (up to 60% ee in CH2Cl2) were obtained with the BINOL-derived ligands L2 and L3 (entries 2 and 3, Table 1).
As mixed donor phosphine–phosphite ligands have been used in the Rh-catalyzed asymmetric hydroformylation38 of styrene, we also tested ligands L1–L3 in this reaction. Excellent branch selectivity was observed for all ligands (Table 2), but poor ee values were obtained. The ee could be slightly improved by changing the Rh/L3 ratio to 1:
2 and increasing the syngas pressure to 30 bar. However, higher L3/Rh ratios did not afford higher ee values (Table 2).
Ligands L1–L3 were also employed in the Rh-catalyzed asymmetric hydrogenation of the trisubstituted functionalized olefin methyl (Z)-2-acetamido-3-phenylacrylate as benchmark substrate (Table 3). Full conversion was achieved with [Rh(COD)2]BF4 and 2 eq. L1 in CH2Cl2, albeit no ee was observed. However, a slight increase in ee (up to 50%, entry 6, Table 3) was observed with L3 as bidentate ligand in THF.
1H NMR (400 MHz, CDCl3): δ 3.92–3.72 (m, 3H), 2.58–2.43 (m, 1H), 2.28–2.21 (m, 1H), 1.73–1.69 (m, 1H), 1.60–1.52 (m, 1H), 1.44–1.38 (m, 1H), 1.20 (s, 3H), 1.15 (s, 3H) ppm. 13C{1H} NMR (100 MHz, CDCl3): δ 88.9, 64.4, 61.3, 51.5, 45.0, 38.6, 36.7, 24.6, 17.2 ppm. 31P{1H} NMR (161 MHz, CDCl3): δ −45.9 (s) ppm. HRMS (ESI-TOF): m/z calculated for C10H18O2P: 201.2367 [M + H]+; observed 201.2249.
L2 (R-BINOL-derived): 1H NMR (400 MHz, CDCl3): δ 8.08–7.91 (m, 4H), 7.59–7.27 (m, 8H), 4.61–4.50 (m, 1H), 3.93–3.90 (m, 1H), 3.78–3.73 (m, 2H), 2.79–2.58 (m, 1H), 2.49–2.40 (m, 1H), 2.20–1.97 (m, 2H), 1.90–1.82 (m, 2H), 1.26 (s, 3H), 1.19 (s, 3H). 13C{1H} (75 MHz, CDCl3): δ 130.6, 128.5, 128.3, 128.0, 127.6, 127.2, 126.4, 125.2, 87.8, 68.1, 64.5, 45.9, 43.5, 38.5, 25.8, 24.7, 18.5. 31P{1H} NMR (122 MHz, CDCl3): δ 135.4 (s) ppm, −44.7 (s) ppm. HRMS (ESI-TOF): m/z calculated for C30H29O4P2: 515.1270 [M + H]+; observed 515.1255. EA: calcd. for C30H28O4P2: C: 70.05, H: 5.50. Found: C: 70.23, H: 5.47.
L3 (S-BINOL-derived): 1H NMR (300 MHz, CDCl3): δ 7.99–7.96 (m, 4H), 7.47–7.32 (m, 8H), 4.38–4.28 (m, 1H), 3.88–3.73 (m, 2H), 3.03 (br, 1H), 2.61–2.54 (m, 1H), 2.32–2.24 (m, 1H), 1.90–1.86 (m, 2H), 1.66–1.52 (m, 2H), 1.22 (s, 3H), 1.17 (s, 3H). 13C{1H} (75 MHz, CDCl3) δ 130.7, 128.3, 128.0, 127.6, 126.4, 87.8, 68.1, 63.1, 45.5, 44.0, 35.3, 25.9, 24.1, 19.3. 31P{1H} NMR (122 MHz, CDCl3): δ 139.4 (s) ppm, −44.7 (s) ppm. HRMS (ESI-TOF): m/z calculated for C30H29O4P2: 515.1271 [M + H]+; observed 515.1193. EA: calcd. for C30H28O4P2: C: 70.05, H: 5.50. Found: C: 70.31, H: 5.37.
1H NMR (400 MHz, CDCl3): δ 8.09–7.93 (m, 4H, H-aryl), 7.58 (m, 1H, H-aryl), 7.55–7.44 (m, 3H, H-aryl), 7.44–7.28 (m, 4H, H-aryl), 4.98 (m, 1H, H-6a), 4.54 (m, 1H, H-6a), 4.11–4.05 (m, 1H, H-5a), 3.90 (m, 1H, H-5a), 2.84 (m, 1H, H-6), 2.40 (m, 1H, H-5), 2.19 (m, 1H, H-2 or 7), 2.10–2.02 (m, 4H, H-2 or 7), 1.97–1.84 (m, 2H, H-2 and 7), 1.25 (s, 3H, H-3a or 4a), 1.18 (s, 3H, H-3a or 4a) ppm; 13C{1H} NMR (101 MHz, CDCl3): δ 132.3 (s, C-quart. aryl), 131.9 (s, C-quart. aryl), 131.6 (s, C-quart. aryl), 131.2 (s, C-aryl), 130.9 (s, C-aryl), 128.5 (s, C-aryl), 128.4 (s, C-aryl), 127.2 (s, C-aryl), 127.0 (s, C-aryl), 126.8 (s, C-aryl), 126.6 (s, C-aryl), 125.8 (s, C-aryl), 121.1 (s, C-aryl), 120.3 (s, C-aryl), 86.1 (d, J = 1.3 Hz, C-quart.), 51.2 (d, J = 18.7 Hz, C-quart.), 66.1 (s, C-5a), 65.6 (dd, C-6a), 46.8 (s, C-5), 42.9 (dd, C-6), 41.6 (d, J = 44.6 Hz, C-2 or 7), 40.3 (d, J = 52.4 Hz, C-2 or 7), 23.8 (d, J = 7.6 Hz, C-3a or 4a), 18.1 (d, J = 16.5 Hz, C-3a or 4a) ppm; 31P{1H} NMR (162 MHz, CDCl3): δ 73.3 (d, J = 2.4 Hz, P-exocyclic), 43.0 (d, J = 2.4 Hz, P-endocyclic) ppm; 31P NMR (162 MHz, CDCl3): δ 73.3 (m, P-exocyclic), 43.0 (m, P-endocyclic) ppm; HRMS (ESI(+), MeCN/CH2Cl2), m/z: found: 579.0986, calculated for [M + H]+: 579.0977; found: 596.1242, calculated for [M + NH4]+: 596.1243; found: 601.0799, calculated for [M + Na]+: 601.0797; found: 1174.2156, calculated for [2 M + NH4]+: 1174.2147; infrared spectrum (KBr): = 3061 (w, C–H aryl), 2923 (w, C–H alkyl), 2855 (w, C–H alkyl), 1740 (w), 1620 (w), 1588 (w), 1505 (w), 1462 (w), 1433 (w), 1375 (w), 1322 (w), 1218 (m), 1199 (m), 1143 (m), 1084 (s), 1068 (s), 1026 (s, C–O stretching in P–O–CH2–C fragment), 1007 (s), 980 (s), 957 (s, P–O stretching in PV–O–Ar fragment), 900 (s), 866 (s), 812 (s), 787 (s), 772 (s), 749 (s), 720 (s), 706 (s), 695 (s), 682 (s), 671 (s, possibly P
S exocyclic), 652 (s, possibly P
S exocyclic), 629 (s, possibly P
S exocyclic), 566 (s), 548 (s), 527 (s), 470 (s), 447 (s) cm−1.
Yield 9b: 172 mg (58%).
1H NMR (400 MHz, CDCl3): δ 8.05 (m, 2H, H-aryl), 7.97 (m, 2H, H-aryl), 7.62–7.52 (m, 1H, H-aryl), 7.51–7.48 (m, 3H, H-aryl), 7.45–7.28 (m, 4H, H-aryl), 4.91 (m, 1H, H-6a), 4.57 (m, 1H, H-6a), 4.01 (m, 1H, H-5a), 3.83 (m, 1H, H-5a), 2.82 (m, 1H, H-6), 2.42 (m, 1H, H-5), 2.30–2.16 (m, 1H, H-2 or 7), 2.13–2.04 (m, 1H, H-2 or 7), 1.99–1.88 (m, 2H, H-2 and 7), 1.26 (s, 3H, H-3a or 4a), 1.19 (s, 3H, H-3a or 4a) ppm; 13C{1H} NMR (101 MHz, CDCl3): δ 132.3 (s, C-quart. aryl), 131.9 (s, C-quart. aryl), 131.6 (s, C-quart. aryl), 131.2 (s, C-aryl), 131.0 (s, C-aryl), 128.5 (s, C-aryl), 128.4 (s, C-aryl), 127.2 (s, C-aryl), 127.0 (s, C-aryl), 126.8 (s, C-aryl), 126.7 (s, C-aryl), 125.8 (s, C-aryl), 122.0 (s, C-aryl), 121.0 (d, J = 3.0 Hz), 120.2 (d, J = 2.7 Hz), 86.1 (s, C-quart.), 65.8 (s, C-5a), 65.3 (dd, C-6a), 51.3 (d, J = 18.5 Hz, C-quart.), 46.8 (s, C-5), 43.0 (dd, C-6), 41.5 (d, J = 44.9 Hz, C-2 or 7), 40.2 (d, J = 52.3 Hz, C-2 or 7), 23.8 (d, J = 7.4 Hz, C-3a or 4a), 18.1 (d, J = 16.1 Hz, C-3a or 4a) ppm; 31P{1H} NMR (162 MHz, CDCl3): δ 73.1 (d, J = 3.5 Hz), 43.2 (d, J = 3.5 Hz) ppm; 31P NMR (162 MHz, CDCl3): δ 73.1 (m, P-endocyclic), 43.2 (m, P-exocyclic) ppm; HRMS (ESI(+), MeCN), m/z: found: 579.0983, calculated for [M + H]+: 579.0977; found: 596.1241, calculated for [M + NH4]+: 596.1243; found: 601.0809, calculated for [M + Na]+: 601.0797; found: 1174.2142, calculated for [2 M + NH4]+: 1174.2147; infrared spectrum (KBr): = 3047 (w, C–H aryl), 2964 (w, C–H alkyl), 2876 (w, C–H alkyl), 1729 (m), 1589 (m), 1508 (m), 1462 (m), 1434 (w), 1371 (w), 1322 (w), 1222 (m), 1198 (w), 1156 (w), 1128 (w), 1072 (m), 1023 (m, C–O stretching in P–O–CH2–C fragment), 980 (s), 954 (s, P–O stretching in PV–O–Ar fragment), 865 (s), 845 (s), 813 (s), 784 (s), 772 (s), 748 (s), 717 (s), 680 (s), 670 (s, possibly P
S exocyclic), 650 (s, possibly P
S exocyclic), 630 (s, possibly P
S exocyclic), 567 (s), 546 (s), 527 (s), 495 (s), 470 (s) cm−1.
Footnotes |
† In memory of Prof. Paul C. J. Kamer. |
‡ Electronic supplementary information (ESI) available. CCDC 2302227. For ESI and crystallographic data in CIF or other electronic format see DOI: https://doi.org/10.1039/d3ra07630j |
§ These two authors contributed equally to this work. |
This journal is © The Royal Society of Chemistry 2023 |